Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Sep;70(3):493–495. doi: 10.1038/bjc.1994.333

Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases?

W Jäger 1, A Kissing 1, S Cilaci 1, R Melsheimer 1, N Lang 1
PMCID: PMC2033344  PMID: 8080736

Abstract

The retrospective analysis of 250 breast cancer patients with disseminated disease provided evidence that the increase in CA 125 serum levels in these patients was caused by lung metastases or pleural effusions. Seven patients with lung metastases and pleural involvement had elevated CA 125 levels, while in four patients with lung metastases but without pleural effusions CA 125 levels remained normal. In patients with only bone or liver metastases CA 125 levels were usually not elevated. If these results are confirmed, CA 125 would be the first tumour marker in breast cancer whose levels could be associated with one single site of metastases.

Full text

PDF
493

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bast R. C., Jr, Knauf S., Epenetos A., Dhokia B., Daly L., Tanner M., Soper J., Creasman W., Gall S., Knapp R. C. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15;68(8):1758–1763. doi: 10.1002/1097-0142(19911015)68:8<1758::aid-cncr2820680819>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  2. Colomer R., Ruibal A., Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer. 1989 Oct 15;64(8):1674–1681. doi: 10.1002/1097-0142(19891015)64:8<1674::aid-cncr2820640820>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  3. Diez M., Cerdàn F. J., Ortega M. D., Torres A., Picardo A., Balibrea J. L. Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer. Cancer. 1991 Jan 1;67(1):150–154. doi: 10.1002/1097-0142(19910101)67:1<150::aid-cncr2820670126>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  4. Einhorn N., Sjövall K., Knapp R. C., Hall P., Scully R. E., Bast R. C., Jr, Zurawski V. R., Jr Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul;80(1):14–18. [PubMed] [Google Scholar]
  5. Hardardottir H., Parmley T. H., 2nd, Quirk J. G., Jr, Sanders M. M., Miller F. C., O'Brien T. J. Distribution of CA 125 in embryonic tissues and adult derivatives of the fetal periderm. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 1):1925–1931. doi: 10.1016/0002-9378(90)90775-3. [DOI] [PubMed] [Google Scholar]
  6. Jäger W., Adam R., Wildt L., Lang N. Serum CA-125 as a guideline for the timing of a second-look operation and second-line treatment in ovarian cancer. Arch Gynecol Obstet. 1988;243(2):91–99. doi: 10.1007/BF00932974. [DOI] [PubMed] [Google Scholar]
  7. Kabawat S. E., Bast R. C., Jr, Bhan A. K., Welch W. R., Knapp R. C., Colvin R. B. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2(3):275–285. doi: 10.1097/00004347-198303000-00005. [DOI] [PubMed] [Google Scholar]
  8. Kandylis K., Vassilomanolakis M., Baziotis N., Papadimitriou A., Tsoussis S., Ferderigou A., Efremidis A. P. Diagnostic significance of the tumour markers CEA, CA 15-3 and CA 125 in malignant effusions in breast cancer. Ann Oncol. 1990 Nov;1(6):435–438. doi: 10.1093/oxfordjournals.annonc.a057798. [DOI] [PubMed] [Google Scholar]
  9. Kimura Y., Fujii T., Hamamoto K., Miyagawa N., Kataoka M., Iio A. Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer. 1990 Oct;62(4):676–678. doi: 10.1038/bjc.1990.355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Niwa Y., Shimokata K. Diagnostic significance of cancer antigen 125, pancreatic oncofetal antigen, and carcinoembryonic antigen in malignant and tuberculous pleural effusions. Jpn J Clin Oncol. 1986 Mar;16(1):3–8. [PubMed] [Google Scholar]
  11. Perey L., Hayes D. F., Tondini C., van Melle G., Bauer J., Lemarchand T., Reymond M., Mach J. P., Leyvraz S. Elevated CA125 levels in patients with metastatic breast carcinoma. Br J Cancer. 1990 Oct;62(4):668–670. doi: 10.1038/bjc.1990.353. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Seckl M. J., Rustin G. J., Coombes R. C. CA-125 is not a useful marker in metastatic breast cancer. Br J Cancer. 1992 Nov;66(5):875–876. doi: 10.1038/bjc.1992.377. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shinozaki T., Chigira M., Kato K. Multivariate analysis of serum tumor markers for diagnosis of skeletal metastases. Cancer. 1992 Jan 1;69(1):108–112. doi: 10.1002/1097-0142(19920101)69:1<108::aid-cncr2820690120>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  14. van Niekerk C. C., Jap P. H., Thomas C. M., Smeets D. F., Ramaekers F. C., Poels L. G. Marker profile of mesothelial cells versus ovarian carcinoma cells. Int J Cancer. 1989 Jun 15;43(6):1065–1071. doi: 10.1002/ijc.2910430619. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES